Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Leber’s hereditary optic neuropathy (LHON) symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer-treating drugs, stress-related chemicals, some antibiotics, and cyanogens.
The LHON pipeline drugs market research report provides an analysis of the LHON drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for LHON and features dormant and discontinued projects.
Key Targets of the LHON Pipeline Drugs Market
Some of the targets of the LHON pipeline drugs market are NADH Ubiquinone Oxidoreductase Chain 4, NADH Ubiquinone Oxidoreductase Chain 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Cardiolipin, Dynamin Like 120 kDa Protein Mitochondrial, Glial Cell Line Derived Neurotrophic Factor, and Nuclear Factor Erythroid 2 Related Factor 2.
LHON Pipeline Drugs Market, by Key Targets
For more insights on key targets, download a free report sample
Key Mechanisms of Action in the LHON Pipeline Drugs Market
The key mechanisms of action of the LHON pipeline drugs market are NADH Ubiquinone Oxidoreductase Chain 4 Activator, NADH Ubiquinone Oxidoreductase Chain 1 Activator, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Dynamin Like 120 kDa Protein Mitochondrial Activator, Glial Cell Line Derived Neurotrophic Factor Activator, and Nuclear Factor Erythroid 2 Related Factor 2 Activator.
LHON Pipeline Drugs Market, by Key Mechanisms of Action
For more insights on key mechanisms of action, download a free report sample
Key Routes of Administration in the LHON Pipeline Drugs Market
The routes of administration in the LHON pipeline drugs market are intravitreal, oral, ophthalmic, intravenous, subcutaneous, and topical.
LHON Pipeline Drugs Market, by Routes of Administration
For more insights on routes of administration, download a free report sample
Key Molecule Types in the LHON Pipeline Drugs Market
The molecule types in the LHON pipeline drugs market are Small Molecule, Gene Therapy, Antisense Oligonucleotide, and Synthetic Peptide.
LHON Pipeline Drugs Market, by Molecule Types
For more insights on molecule type, download a free report sample
Key Companies in the LHON Pipeline Drugs Market
Some of the key companies in the LHON pipeline drugs market are GenSight Biologics SA, Neurophth Therapeutics Inc, Biovista Inc, Ixchel Pharma LLC, Astellas Pharma Inc, Evvia Therapeutics Inc, Imbria Pharmaceuticals Inc, and Metro International Biotech LLC among others.
LHON Pipeline Drugs Market, by Companies
For more insights on companies, download a free report sample
LHON Pipeline Drugs Market Report Overview
Key Targets | NADH Ubiquinone Oxidoreductase Chain 4, NADH Ubiquinone Oxidoreductase Chain 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Cardiolipin, Dynamin Like 120 kDa Protein Mitochondrial, Glial Cell Line Derived Neurotrophic Factor, and Nuclear Factor Erythroid 2 Related Factor 2 |
Key Mechanisms of Action | NADH Ubiquinone Oxidoreductase Chain 4 Activator, NADH Ubiquinone Oxidoreductase Chain 1 Activator, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Dynamin Like 120 kDa Protein Mitochondrial Activator, Glial Cell Line Derived Neurotrophic Factor Activator, and Nuclear Factor Erythroid 2 Related Factor 2 Activator |
Key Routes of Administration | Intravitreal, Oral, Ophthalmic, Intravenous, Subcutaneous, and Topical |
Key Molecule Types | Small Molecule, Gene Therapy, Antisense Oligonucleotide, and Synthetic Peptide |
Key Companies | GenSight Biologics SA, Neurophth Therapeutics Inc, Biovista Inc, Ixchel Pharma LLC, Astellas Pharma Inc, Evvia Therapeutics Inc, Imbria Pharmaceuticals Inc, and Metro International Biotech LLC |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Biovista Inc
Evvia Therapeutics Inc
GenSight Biologics SA
Imbria Pharmaceuticals Inc
Ixchel Pharma LLC
Metro International Biotech LLC
Mitotech SA
Neurophth Therapeutics Inc
Neuroptika Inc
PYC Therapeutics Ltd
Stealth BioTherapeutics Corp
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the LHON pipeline drugs market?
Some of the targets of the LHON pipeline drugs market are NADH Ubiquinone Oxidoreductase Chain 4, NADH Ubiquinone Oxidoreductase Chain 1, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase, Cardiolipin, Dynamin Like 120 kDa Protein Mitochondrial, Glial Cell Line Derived Neurotrophic Factor, and Nuclear Factor Erythroid 2 Related Factor 2.
-
What are the mechanisms of action of the LHON pipeline drugs market?
The key mechanism of action of the LHON pipeline drugs market are NADH Ubiquinone Oxidoreductase Chain 4 Activator, NADH Ubiquinone Oxidoreductase Chain 1 Activator, Adenosine Monophosphate Activated Protein Kinase ([Hydroxymethylglutaryl CoA Reductase Activator, Dynamin Like 120 kDa Protein Mitochondrial Activator, Glial Cell Line Derived Neurotrophic Factor Activator, and Nuclear Factor Erythroid 2 Related Factor 2 Activator.
-
What are the routes of administration in the LHON pipeline drugs market?
The routes of administration in the LHON pipeline drugs market are intravitreal, oral, ophthalmic, intravenous, subcutaneous, and topical.
-
What are the molecule types in the LHON pipeline drugs market?
The molecule types in the LHON pipeline drugs market are Small Molecule, Gene Therapy, Antisense Oligonucleotide, and Synthetic Peptide.
-
Which are the key companies in the LHON pipeline drugs market?
Some of the key companies in the LHON pipeline drugs market are GenSight Biologics SA, Neurophth Therapeutics Inc, Biovista Inc, Ixchel Pharma LLC, Astellas Pharma Inc, Evvia Therapeutics Inc, Imbria Pharmaceuticals Inc, and Metro International Biotech LLC among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.